regeneron semaglutide Combinations Show Promise in Phase 2 COURAGE Obesity Trial Regeneron takes aim at Zepbound

Cardiovascular Risk Indication In 2024, semaglutide 2.4 mg (Wegovy) received an additional FDA indication: reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight

Nutrition and growth

A casecontrol study involving 58 PD patients compared to 20 healthy controls showed that IL-1, TNF-, IL-6, CRP, and IL-12 are increased in PD patients compared to healthy controls (Kim et al

In mice, this formulation increased fecal butyrate, which in turn stimulated GLP-1 release from L-cells, reducing food intake and improving glucose tolerance and insulin sensitivity

McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M

Microbial Ecol Health Dis